Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease

We describe a bispecific dual-antagonist antibody against human B cell activating factor (BAFF) and interleukin 17A (IL-17). An anti-IL-17 single-chain variable fragment (scFv) derived from ixekizumab (Taltz®) was fused via a glycine-rich linker to anti-BAFF tabalumab. The IgG-scFv bound both BAFF a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Benschop, Robert J., Chow, Chi-Kin, Tian, Yu, Nelson, James, Barmettler, Barbra, Atwell, Shane, Clawson, David, Chai, Qing, Jones, Bryan, Fitchett, Jon, Torgerson, Stacy, Ji, Yan, Bina, Holly, Hu, Ningjie, Ghanem, Mahmoud, Manetta, Joseph, Wroblewski, Victor J., Lu, Jirong, Allan, Barrett W.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2019
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6748573/
https://ncbi.nlm.nih.gov/pubmed/31181988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1624463
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados